Drugs / HSK42360-Na
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07561554 | Mar 2026 → Dec 2028 expected | — | Haisco Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK42360-Na | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07561554 ↗ |
| Route | Oral | “Oral administration” NCT07561554 ↗ |